Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Acupuncture Research ; (6)2010.
Article in Chinese | WPRIM | ID: wpr-580832

ABSTRACT

Objective To observe the effect of electroacupuncture(EA) in combination with small dose of clozapine on clinical symptoms of refractory schizophrenia patients so as to evaluate its validity and security.Methods Eighty schizophrenia patients were randomized into medication group and EA+medication group(n=40/group).Patients of medication group were treated with conventional oral administration of clozapine(50-100 mg/d to 200-500 mg/d,for 8 weeks) and those of EA+ medication group treated by EA of Baihui(GV 20) and bilateral Taiyang(EX-HN 5) and oral administration of clozapine(50 mg/d to 100-150 mg/d).EA was given to the patients,3 times a week for 8 weeks.Scores of the Positive and Negative Symptom Scale(PANSS) and the Untoward Effect Symptom Scale(TESS) were used to assess the therapeutic effect.Results Following treatment,PANSS scores for positive symptoms and the common psychiatric symptoms of the medication and EA+medication groups all decreased evidently from the 2rd week on(P0.05).But TESS score of EA+medication group was evidently lower than that of medication group(P

2.
China Pharmacy ; (12)2005.
Article in Chinese | WPRIM | ID: wpr-533979

ABSTRACT

OBJECTIVE: To evaluate the efficacy and ADR of palipeddone sustained release tablet in the treatment of schizophrenia in outpatient. METHODS: Outpatients with schizophrenia treated with palipeddone sustained release tablet(observation group) in our hospital from Apr. to Sep. in 2009 were followed up and compared with those treated with risperidone(control group) during the same period. PANSS and TESS were applied to evaluate efficacy and ADR. RESULTS: The cure rates were 42.4% for control group and 49.6% for observation group. The effective rates were 74.8% for control group and 80.3% for observation group (P

SELECTION OF CITATIONS
SEARCH DETAIL